Sysmex Corporation

Equities

6869

JP3351100007

Medical Equipment, Supplies & Distribution

Market Closed - Japan Exchange 02:00:00 2024-04-23 am EDT 5-day change 1st Jan Change
2,488 JPY +1.53% Intraday chart for Sysmex Corporation +0.79% -5.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sysmex to Carry Out 3-for-1 Stock Split; Shares Jump 4% MT
Sysmex Corporation Reports Earnings Results for the Nine Months Ended December 31, 2023 CI
Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Cellavision, Sysmex Expand Hematology Partnership Deal MT
CellaVision and Sysmex Corporation Sign Strategic Alliance Agreement CI
Germany’s USU Software Signs Knowledge Management Deal with Japan’s Sysmex MT
Jefferies Adjusts Sysmex’s Price Target to 8,500 Yen From 8,800 Yen, Keeps at Hold MT
Sysmex Corporation acquired additional unknown stake in Megakaryon Corporation. CI
Fujirebio Holdings, Inc. and Sysmex Corporation Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay CI
VCCT Inc announced that it has received ¥600 million in funding from YASKAWA Electric Corporation, Dai-Dan Co., Ltd., Sysmex Corporation CI
Sysmex Unit Plans to Acquire Shares in IVD Medical's Subsidiary MT
New entries in MarketScreener's Asia portfolio Our Logo
Fujirebio Holdings, Inc. and Sysmex Corporation Enter into Basic Agreement on Business Collaboration in the Field of Immunoassay CI
Dpa-AFX Overview: COMPANIES of 03.08.2023 - 15.15 o'clock DP
Sysmex Corporation Announces Management Changes CI
Jefferies Adjusts Sysmex’s Price Target to 8,200 Yen From 7,300 Yen, Keeps at Hold MT
Sysmex America, Inc. Appoints Chris Cappella as Chief Financial Officer CI
High Inflation Makes Japanese Stocks Bleed Losses; Toshiba Rises 2% as Bidder Moves Closer to Securing Buyout Funding MT
Sysmex says Japan approves blood test for Alzheimer's marker RE
Japan Index Witnesses Strong Buying; Shares of Sysmex, JCR Pharmaceuticals Expand 4% on Regenerative Medicine JV MT
Shares of JCR Pharmaceuticals, Sysmex Expand 4% on Regenerative Medicine JV MT
Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy CI
New entries in the Asia Investor portfolio Our Logo
UBS Adjusts Sysmex's Price Target to 11,300 Yen From 12,500 Yen, Keeps at Buy MT
Sysmex Shares Jump After Fiscal-Year Net Profit Rose 38% DJ
Chart Sysmex Corporation
More charts
Sysmex Corp is a Japan-based company principally engaged in the health care business. The Company conducts product development, manufacturing, sales, and service in domestic markets, and some products are developed, manufactured, and sold by subsidiaries. Overseas, the Company conducts the manufacturing and sales of products in the Americas, EMEA, China, and Asia Pacific through other companies. Along with its subsidiaries, the Company is involved in the development, manufacture, sale and service of clinical laboratory equipment, laboratory test drugs and products related to laboratory test.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
2,450 JPY
Average target price
3,050 JPY
Spread / Average Target
+24.48%
Consensus
  1. Stock Market
  2. Equities
  3. 6869 Stock
  4. News Sysmex Corporation
  5. UBS Adjusts Sysmex's Price Target to 12,500 Yen From 14,600 Yen, Keeps at Buy